MIF-1 is active in a chronic stress animal model of depression

Pignatiello, Michael F.; Olson, Gayle A.; Kastin, Abba J.; Ehrensing, Rudolph H.; McLean, Jack H.; Olson, Richard D.

doi:10.1016/0091-3057(89)90027-0

Cited by 37 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This tripeptide has been identiÞed as a neuropeptide in laboratory studies and there is also some evidence for a PGL receptor in the rat brain (see Reed et al 1994). There are numerous reports on antidepressant-like e¤ects of PLG in animal studies (see Pignatiello et al 1989), and from a recent clinical double-blind study showing substantial antidepressant properties of this terminal side-chain tripeptide of oxytocin (Ehrensing et al 1994).…”

Section: Methodological Issuesmentioning

confidence: 95%

Oxytocin as a possible mediator of SSRI-induced antidepressant effects

et al. 1999

View full text Add to dashboard Cite

The nonapeptide oxytocin is released into systemic circulation in situations of psychosocial interaction, and has been shown to be involved in mechanisms of social bonding and social recognition in laboratory studies. In view of disturbances in psychosocial relationships being a triggering factor for depression and anxiety, it is interesting to note that experimental studies have shown oxytocin to possess antidepressant- and anxiolytic-like actions. Thus. in the present study we examined effects of the SSRI citalopram (20 mg/kg i.p.) on plasma oxytocin, acutely and upon repeated administration, in adult male Sprague-Dawley rats. Plasma oxytocin, and some functionally related peptides (CCK, gastrin, somatostatin and insulin), were measured by standard radioimmunoassay techniques. Acute citalopram administration produced a statistically significant increase in plasma oxytocin and CCK levels. Administration of citalopram for 14 days did not attenuate the oxytocin-releasing effect to a challenge dose of the SSRI zimeldine (20 mg/kg s.c.), whereas CCK levels were not increased after the subchronic citalopram treatment. Thus, the SSRI citalopram produces increased plasma oxytocin levels acutely, and there appears to be no or little tolerance to this effect upon repeated administration. There were no, or variable, effects on plasma levels of gastrin, somatostatin or insulin. It is suggested that oxytocin release is an important aspect of the pharmacological actions of SSRIs, and this could be an important contributory factor for the clinical profile of this group of antidepressants with particular efficacy in disorders of psychosocial origin.

show abstract

Section: Methodological Issuesmentioning

confidence: 95%

Oxytocin as a possible mediator of SSRI-induced antidepressant effects

et al. 1999

View full text Add to dashboard Cite

show abstract

“…The striatum is also involved in mental depression [28,31,43,46], and known antidepressants are effective in some of the animal tests for Parkinson’s disease in which MIF-1 is active [22,23,37-41,51]. MIF-1 is also effective in more specific models of depression [21,24,26,27,33,36,42] and has shown great promise in clinical trials of depression, characterized by an early onset of improvement [15-17,49]. …”

Section: Discussionmentioning

confidence: 99%

Mass spectrometric quantification of MIF-1 in mouse brain by multiple reaction monitoring

Kheterpal

Kastin

Mollah³

et al. 2009

Peptides

Self Cite

View full text Add to dashboard Cite

MIF-1 (Pro-Leu-Gly-NH2) has potent therapeutic effects in depression and Parkinson’s disease, but its CNS sites of production are not yet clear. In this study, the concentration of MIF-1 in different brain regions was measured by the multiple reaction monitoring technique on a 4000 QTRAP mass spectrometer. The limit of quantification was 300 fg of MIF-1, and limit of detection was 60 fg. The low molecular weight fractions of tissue homogenates from different regions of mouse brain were analyzed. The concentration of MIF-1 ranged from 22 ± 3 fg/μg protein in cerebral cortex to 930 ± 60 fg/μg protein in the hypothalamus. Moderate concentrations were also detected in all other regions tested, including the striatum, thalamus, and hippocampus. By incubation of stable isotope-labeled oxytocin with tissue preparations, it was also confirmed that oxytocin at least partially contributed to the production of MIF-1 in the hypothalamus by action of peptidases. Regional differences were also found. The results are the first to show the ultrasensitive quantification of MIF-1 in different brain regions, and support the neuromodulatory actions of MIF-1 in the striatum.

show abstract

“…In other models in which antidepressants are active, Niesink and van Ree found that MIF-1 reversed isolation-induced increase in social activity [48], and Dutch researchers also reported that MIF-1 antagonized melatonin-induced behavioral changes [49]. MIF-1 is also effective in the labor-intensive Katz test of unpredictable chronic stress [50,51]. …”

Section: Conceptsmentioning

confidence: 99%

Concepts for Biologically Active Peptides

Kastin¹,

Pan²

2010

CPD

View full text Add to dashboard Cite

Here we review a unique aspect of CNS research on biologically active peptides that started against a background of prevalent dogmas but ended by exerting considerable influence on the field. During the course of refuting some doctrines, we introduced several concepts that were unconventional and paradigm-shifting at the time. We showed that (1) hypothalamic peptides can act ‘up’ on the brain as well as ‘down’ on the pituitary, (2) peripheral peptides can affect the brain, (3) peptides can cross the blood-brain barrier, (4) the actions of peptides can persist longer than their half-lives in blood, (5) perinatal administration of peptides can exert actions persisting into adulthood, (6) a single peptide can have more than one action, (7) dose-response relationships of peptides need not be linear, (8) the brain produces antiopiate as well as opiate peptides, (9) there is a selective high affinity endogenous peptide ligand for the mu-opiate receptor, (10) a peptide’s name does not restrict its effects, and (11) astrocytes assume an active role in response to metabolic disturbance and hyperleptinemia. The evolving questions in our laboratories reflect the diligent effort of the neuropeptide community to identify the roles of peptides in the CNS. The next decade is expected to see greater progress in the following areas: (a) interactions of peptides with other molecules in the CNS; (b) peptide involvement in cell-cell interactions; and (c) peptides in neuropsychiatric, autoimmune, and neurodegenerative diseases. The development of peptidomics and gene silencing approaches will expedite the formation of many new concepts in a new era.

show abstract

MIF-1 is active in a chronic stress animal model of depression

Cited by 37 publications

References 24 publications

Oxytocin as a possible mediator of SSRI-induced antidepressant effects

Oxytocin as a possible mediator of SSRI-induced antidepressant effects

Mass spectrometric quantification of MIF-1 in mouse brain by multiple reaction monitoring

Concepts for Biologically Active Peptides

Contact Info

Product

Resources

About